This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Haemonetics To Provide An Update On Key Growth Initiatives At J.P. Morgan Health Care Conference

Stocks in this article: HAE

BRAINTREE, Mass., Jan. 4, 2013 /PRNewswire/ -- 

  • Whole Blood Acquisition Integration Ahead of Schedule
  • Paperless Phlebotomy On Track For Limited Market Release in Q4 Fiscal 2013
  • OrthoPAT ® Advance Receives 510K Approval
  • Emerging Market Investments Driving Growth in TEG ® and Cell Salvage
  • Customer Adoption of Blood Management Solutions Driving Hospital Growth
  • Hemerus Medical Remains on Track To Respond To FDA's SOLX ® Questions

Haemonetics Corporation (NYSE: HAE) today announced significant progress on key business initiatives in conjunction with the 31 st Annual J.P. Morgan Health Care Conference in San Francisco.  Brian Concannon, President and CEO of Haemonetics, will discuss these initiatives as part of a live webcast presentation at 4:30PM Pacific time / 7:30PM Eastern time on Wednesday, January 9.  

(Logo: )

"Our current fiscal year 2013 is a landmark year in which we completed the largest acquisition in our company's history, the whole blood collection, filtration and processing business from Pall Corporation.  Subsequently, we have integrated it seamlessly with no interruption to customer needs", said Mr. Concannon.  "We also remain on track for the introduction of the first element of automation into that market later in fiscal 2013, in the form of paperless phlebotomy.  At the same time, we made considerable advances in blood management solutions for our customers. In this regard, we prepared for the first half of fiscal 2014 introduction of our recently approved OrthoPAT Advance device into the hospital market and our investments in emerging markets have boosted our TEG and Cell Saver ® Elite ® penetration there as well." 

Whole Blood Acquisition Integration Since the August 1, 2012 completion of the Whole Blood acquisition, 17 internal cross-functional integration teams have pursued all elements of integration to ensure that critical business functions including IT, supply chain, quality and regulatory compliance to name a few continued effectively.  The integration effort is ahead of schedule and is expected to be substantially completed by the end of fiscal 2013.

Paperless Phlebotomy For Whole Blood Collection The company has previously revealed plans to introduce its paperless phlebotomy product offering into the whole blood market, which is the first phase of their Automated Whole Blood product launch.  This consists initially of a software platform that allows collection of donation data at the chair side using a wireless hand-held/tablet device, followed by a communications tower permitting wireless connectivity in even the most difficult blood collection locations, and required connectivity software.  The paperless phlebotomy product is the first of three product launch phases that collectively facilitate the ability to automate the process of collecting whole blood.  FDA clearance of the paperless phlebotomy offering and limited market release to an identified U.S. blood center customer are expected to occur by the end of Q4 of fiscal 2013 as anticipated.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs